A real‐world data of Immune checkpoint inhibitors in solid tumors from India

A real‐world data of Immune checkpoint inhibitors in solid tumors from India

Abstract Background Checkpoint inhibitors (Nivolumab and Pembrolizumab) are approved for multiple indications in solid tumors. However access to these therapies is limited in low and middle income countries. Hence we performed an audit to identify accessibility, adverse event rates, compliance, prog...

Full description

Bibliographic Details
Main Authors: Vanita Noronha, George Abraham, Vijay Patil, Amit Joshi, Nandini Menon, Abhishek Mahajan, Amit Janu, Srushti Jain, Vikas T Talreja, Akhil Kapoor, Gunjesh Kumar Singh, Satvik Khaddar, Kushal Gupta, Narmadha Rathinasamy, Sujay Srinivas, Amit Agrawal, Pradeep Ventrapati, Kumar Prabhash
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Cancer Medicine
Subjects:
checkpoint inhibitors
CPI
hepatitis
Immunotherapy
India
irAE
Online Access:https://doi.org/10.1002/cam4.3617

Internet

https://doi.org/10.1002/cam4.3617

Similar Items